On August 6, the Federal Trade Commission (FTC) challenged Edwards Lifesciences Corp.'s proposed $945 million acquisition of JenaValve Technology, Inc. The deal would combine the two leading companies competing to develop...more
Many observers viewed the FTC’s case challenging the Tapestry/Capri merger based on a relevant product market of “accessible luxury handbags” with skepticism. The market definition seemed (and still seems) gerrymandered to...more
The suit of a merger that had already cleared HSR review serves as a reminder that parties should not assume clearance confers immunity from scrutiny. Update: On September 26, 2017, the US Department of Justice’s...more